Sunday, March 19, 2006

“one five-hundredth of the dose used in monkeys”

Blacktriangle presents thorough updates on the trouble in the UK clinical trials of TGN1412, an experimental monoclonal antibody, which has been in the headlines this week outside of the US.

Update: Uh-oh. We'll see if it sticks.

0 comments:

Post a Comment